ZEISS METROTOM 6 scout Now Available at Exact Metrology

Exact Metrology, a comprehensive 3D metrology service provider and hardware sales company, has recently installed a ZEISS METROTOM 6 scout, formally known as a GOM CT, scanner at their facility in Brookfield, Wisconsin.

Considered the powerhouse of resolution for CT inspection and metrology, the METROTOM 6 scout digitizes complex parts including the internal geometries at the finest level of detail. Users obtain a complete 3D image for GD&T analysis or nominal-actual comparisons. The metrology CT excels in digitizing small plastic parts.

The combination of a 3k detector and 225 kV X-ray enables ZEISS METROTOM 6 scout to provide high contrast, high-resolution measurement results and exceptional sharpness of detail. As a result, even the smallest defects in the part become visible and can be analyzed to the last detail.

To showcase the ability of Exact Metrology’s CT scanning services, powered by the METROTOM 6 scout, a scan was done on a medical stent. This medical stent, with a diameter of only 1 millimeter, was measured within a 5 Micron resolution. Thus, Exact Metrology inspectors were able to evaluate critical features with amazing precision.

CT scanning provides several benefits including being the only way to get 3D views inside a part and the only way to obtain accurate dimensional data without cutting up and destroying an object. In addition, CT scanning requires very little time to capture data and troubleshoot parts and also offers multiple uses with one scan (void analysis, inspection, volume, porosity, reverse engineering, etc.). In contrast to conventional tactile coordinate measurement techniques, a CT acquires all surface points simultaneously —on even the most complex objects. This includes all hidden features like undercuts which are not accessible using other non-destructive measurement methods.

Due to its ability to see data layer by layer, CT scanning permitted Exact Metrology inspectors the ability to see any possible defects/details on the stent. This is crucial for any medical device, especially something as small and essential as a stent that goes into the human body.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version